#POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab) -> Only nail dystrophy OR: 3 (150mg) OR: 5 (300mg) 🤔But why? #EULAR2021 @RheumNow https://t.co/srb6jGgBqe